Результаты поиска

Matrix stimulation in cancer pain: Methodology, safety and effectiveness.

BackgroundThis feasibility study addresses the applicability of matrix electrodes for the reduction of ongoing pain in cancer patients via low-frequency electrical stimulation (LFS).MethodsLow-frequency matrix stimulation (4 Hz) was applied to the skin within the 'Head's zones' referring to the tumour localization of cancer pain patients. Pain at baseline was compared to a 3-day treatment interval consisting of 5 min of matrix stimulation in the morning and evening followed by a 3-day follow-up period without therapy. Main outcome parameters included numeric rating scale values (rating scale 0

Совпадение в полном тексте источника
… Breakthrough pain in malignant and non‐malignant diseases: A review of prevalence, characteristics and mechanisms. Eur J Pain 9, 195–206. Veiga, V.F. , Nimrichter, L. , Teixeira, C.A. , Morales, M.M. , Alviano, C.S. , Rodrigues, M.L. , Holandino, C. (2005). … Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20, 87–92. …

Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.

First-in-class (FIC) drugs are considered the main drivers of new drug discovery and have novel targets and mechanisms. The proportion of FIC drugs among new drugs provides fundamental guidance for both academic and pharmaceutical research. From a global perspective, 81 FIC drugs were approved in 2023 and 2024. Among them, small-molecule drugs account for a greater percentage (51.9%), illustrating the discovery of new chemical entities. Macromolecule drugs (48.1%), which mainly consist of antibody analogs, represent a growing trend as new biotechnology techniques have emerged. In terms of FIC

Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, i

Global Panoramic analysis of clinical research in cell therapy: clinical trial landscape, marketed products, and regulatory trends.

IntroductionCell therapy is a vital field in modern medicine. This review assesses its global clinical development landscape, approved products, and regional regulatory characteristics.MethodsA comprehensive search and analysis of global clinical trial databases (e.g., https://clinicaltrials.gov/ClinicalTrials.gov), regulatory agency announcements, and relevant literature up to October 2025 was conducted. Key data points regarding trial numbers, phases, therapy types, and approved products were extracted and analyzed descriptively by region.ResultsA cumulative total of 10,373 cell therapy clin

Infections in Recipients of Hematopoietic Stem Cell Transplants

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Antibodies to watch in 2022.

In this 13th annual installment of the annual 'Antibodies to Watch' article series, we discuss key events in commercial antibody therapeutics development that occurred in 2021 and forecast events that might occur in 2022. Regulatory review of antibody therapeutics that target the SARS-CoV-2 coronavirus proceeded at an unprecedented pace in 2021, resulting in both emergency use authorizations and full approvals for sotrovimab, regdanvimab, REGEN-COV2, as well as others, in numerous countries. As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the Un

Antibodies to watch in 2023.

In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevim

Nirogacestat and its potential impact on desmoid tumor.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM).

BackgroundTherapy choices in relapsed/refractory multiple myeloma (RRMM) should consider patient satisfaction with treatment, because it is associated with adherence to therapy, health outcomes, and medical safety. The primary objective of this pilot cross-sectional observational study was to ascertain factors associated with patient-reported treatment satisfaction in RRMM.Patients and methodsPatients with a self-reported diagnosis of RRMM recruited from PatientsLikeMe, MyelomaCrowd, and Facebook were administered an electronic survey that included questions on demographics and clinical histor

Совпадение в полном тексте источника
… In an exploratory analysis of data from a multicenter, open‐label, long‐term study of fentanyl pectin nasal sprays, patients with breakthrough pain in cancer who had higher performance score (lower ECOG) reported higher satisfaction with treatment [ 16 ]. … Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer . J Palliat Med 2014 ; 17 : 1150 – 1157 . 25211772 10.1089/jpm.2014.0089 17 Hitz F , Klingbiel D , Ribi K. …

Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.

PurposeTo discuss new therapeutic strategies for chemotherapy-induced nausea and vomiting (CINV) involving 5-hydroxytryptamine type 3 (5HT3)-receptor antagonists (RAs).SummaryCINV remains poorly controlled in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC); nausea and delayed-phase CINV (24-120 hours after chemotherapy) are the most difficult to control. National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) antiemesis-guideline recommendations for HEC include a four-drug regimen (5HT3 RA, neurokinin 1 [

Monoclonal Antibodies Approved for Cancer Therapy

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience

Abstract Background Patients with hematological malignancies are a heterogeneous group with special palliative care needs. They are known to have many symptoms and frequent emergency room visits and hospitalizations in the end-of-life phase. However, there are limited data about the symptom burden and health care service utilization in different diagnostic groups of hematological malignancies. Objectives The purpose of this study was to define the symptom burden and characteristics of the palliative care phase in patients with hematological malignancies in different diagnostic groups. Methods

Дилопия и экстремальная гиперамиласемия>100,000 U/L) Провозглашение агрессивного поведения ИгГ каппы миэломы: доклад о деле и обзор литературы.

RATALE: Хотя производство амилазы эпителиальными опухолями было хорошо задокументировано, его связь с множественной миеломой (ММ) является крайне редкой, о чем сообщалось лишь ограниченное число случаев. Кроме того, насколько нам известно, информация о бинокльной диплопии в качестве известной и первичной клинической функции у пациентов с MM и одновременно гиперамиласемией не получила широкого распространения. ОЗАБОЧЕННОСТЬ: В настоящем докладе содержится описание 75-year-old человек с иммуноглобулином G kappa MM, поражающим диплопию и экстремальную гиперамиласемию ()>100,000 U/L) с нормальным

"Anecdotal evidence": why narratives matter to medical practice.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

A case report of metastatic hepatocellular carcinoma in the mandible and coracoid process: A rare presentation.

RationaleWe report a rare case of hepatocellular carcinoma (HCC) with metastases to the mandible and coracoid process of scapula without evidence of lung involvement.Patients concernsThe patient was diagnosed with HCC, presented 5 months later with right lower tooth pain, swelling over the right mandible area and right shoulder pain.DiagnosesHistopathological examination of mandible showed findings suggestive of metastatic HCC. Magnetic resonance imaging (MRI) of the right shoulder revealed findings of irregular enhancing lesion at the right coracoid process causing erosion of the coracoid pro

Management of infection and ocular complications in pediatric SJS/TEN-like acute graft-versus-host disease: a clinical case study and literature review.

Acute graft-versus-host disease (aGVHD) with skin manifestations reminiscent of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) is associated with poor outcomes. However, optimal management strategies to enhance quality of life in SJS/TEN-like aGVHD remain undefined. This study aims to investigate the management of complex infections and acute ocular injury in patients with SJS/TEN-like aGVHD following allogeneic hematopoietic stem cell transplantation. We conducted a comprehensive analysis of the treatment course for a patient with SJS/TEN-like aGVHD, complemented by a lit

Impact of genetic polymorphisms on the response to transdermal fentanyl in cancer patients-a single-center, prospective, biological study.

BACKGROUND/OBJECTIVES: Transdermal fentanyl (TDF) is widely used for moderate-to-severe cancer pain, yet substantial variability in fentanyl exposure, analgesic response, and tolerability remains incompletely explained by clinical factors. We evaluated whether pharmacogenetic variability is associated with pharmacokinetic parameters and clinical outcomes in cancer patients receiving TDF. METHODS: In this prospective, single-center study, adults with solid or hematological malignancies and chronic cancer pain treated with stable-dose 72 h TDF were enrolled. Blood samples were collected for pha

Совпадение в полном тексте источника
… Breakthrough pain and AEs were managed according to standard clinical practice. All patients received verbal and written information and provided written informed consent. … Clinical data collected included age, sex, tumor type and stage, body mass index (BMI), Eastern Cooperative Oncology Group performance status (ECOG PS), hydration status, concomitant medications, fentanyl dose, AEs, and opioid use for breakthrough pain. …

A multidisciplinary bone metastases clinic at Toronto Sunnybrook Regional Cancer Centre - A review of the experience from 1999 to 2005.

Our objective in this study was to review the experience of a one-stop multidisciplinary bone metastases clinic (BMC) that offers a coordinated multidisciplinary approach to the care of cancer patients with bone metastases in a tertiary cancer centre. Patients with symptomatic bone metastases were referred to BMC and assessed by a team of specialists in various disciplines - interventional radiology, orthopedic surgery, palliative medicine, and radiation oncology. At initial consultation, patient demographics, reasons for referral, and case disposition were recorded. From January 1999 to Febru

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma.

BACKGROUND: Patients with multiple myeloma (MM) experience disabling symptoms that are difficult to manage and may persist after induction therapy. Monitoring disease-related and induction therapy-induced symptoms and identifying patients at greater risk for high symptom burden are unmet clinical needs. The objective of this study was to examine the trajectories of symptom severity over time and identify predictors of high symptom burden during MM induction therapy. METHODOLOGY: Eligible patients with MM rated their symptoms by completing the MD Anderson Symptom Inventory MM module repeatedly

Совпадение в полном тексте источника
… Opioid use compromises QOL in patients with MM [ 46 ] and carries risks for constipation, breakthrough pain requiring hospitalization, and opioid misuse and tolerance [ 47 , 48 ]. … Bujedo BM Karlsson B Fentanyl in a pectin gel treating breakthrough pain in vertebral compression fracture due to multiple myeloma: a descriptive study of three cases J Opioid Manag 2016 12 3 197 203 10.5055/jom.2016.0332 27435440 Bujedo BM, Karlsson B (2016) Fentanyl in a pectin gel treating breakthrough …

Pharmacological Treatments and Therapeutic Drug Monitoring in Patients with Chronic Pain.

Pain is an unpleasant sensory and emotional experience that affects every aspect of a patient's life and which may be treated through different pharmacological and non-pharmacological approaches. Analgesics are the drugs most commonly used to treat pain, and in specific situations, the use of opioids may be considered with caution. These drugs, in fact, do not always induce optimal analgesia in patients, and several problems are associated with their use. The purpose of this narrative review is to describe the pharmacological approaches currently used for the management of chronic pain. We rev

Совпадение в полном тексте источника
… Furthermore, the pain’s intensity (mild, moderate, or severe) and persistence (acute, chronic or breakthrough pain) is considered [ 31 ]. … The oral bioavailability of buprenorphine is very low and highly variable [ 100 ]; buccal film and sublingual tablets are used to treat breakthrough pain (BTP) [ 140 ], while a transdermal patch is used for chronic pain relief [ 135 ]. …